GlassScriptPhysician profile
Anthony W Mimms
NPI 1952383887
$10,187.07
in general payments reported to CMS, 2019-2025
38 companies · $167 in 2025
The $167 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,716 · 2020: $1,424 · 2021: $2,792 · 2022: $781 · 2023: $608 · 2024: $699 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,474.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $3,058.74 | 2019 | |
| Redhill Biopharma INC. | $1,684.69 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,141.35 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $638.46 | 2019-2025 | Xtampza |
| Mdd US Operations, LLC | $500.00 | 2020 | |
| Horizon Therapeutics Plc | $466.47 | 2019-2022 | |
| Abbvie INC. | $398.78 | 2021-2024 | |
| Arbor Pharmaceuticals, INC. | $267.25 | 2019-2022 | |
| Grt US Holding, INC. | $258.53 | 2021-2022 | |
| Pfizer INC. | $235.91 | 2019-2025 | |
| Eisai INC. | $189.40 | 2021 | |
| Lilly USA, LLC | $129.35 | 2019-2021 | |
| Allergan, INC. | $121.66 | 2020 | |
| Orexo US, INC. | $114.50 | 2019-2024 | Zubsolv |
| Amgen INC. | $110.45 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $92.21 | 2020-2025 | Sublocade |
| Supernus Pharmaceuticals, INC. | $86.48 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.92 | 2022 | |
| Scilex Pharmaceuticals INC. | $58.68 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $57.88 | 2019 | |
| Idorsia Pharmaceuticals US INC | $50.22 | 2023 | Quviviq |
| Azurity Pharmaceuticals, INC. | $49.45 | 2024 | Horizant |
| Tersera Therapeutics LLC | $46.32 | 2019 | |
| Biodelivery Sciences International, INC. | $44.62 | 2020-2021 | |
| Almatica Pharma LLC | $41.35 | 2021 | |
| Virtus Pharmaceuticals LLC | $36.12 | 2021 | |
| Smith+Nephew, INC. | $34.41 | 2019 | |
| Boston Scientific Corporation | $30.04 | 2021-2024 | |
| Daiichi Sankyo INC. | $26.00 | 2019 | |
| Ibsa Pharma INC. | $23.87 | 2021 | |
| Shionogi INC | $22.93 | 2019 | |
| Harmony Biosciences LLC | $20.48 | 2023 | Wakix |
| Abbott Laboratories | $19.35 | 2024 | Proclaim |
| Si-Bone, INC. | $17.57 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.04 | 2021 | |
| Zyla Life Sciences, INC. | $12.99 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.10 | 2019 | |
| Kerecis Limited | $11.50 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Mimms listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.